Intensity Therapeutics has administered INT230-6 in the INVINCIBLE-4 Study in Switzerland. The clinical biotechnology company is focused on the discovery and development of novel intratumoural cancer therapies that are designed to kill tumours and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology.

The trial (NCT06358573) analyses INT230-6 given before administration of the standard-of-care neoadjuvant immuno-chemotherapy (“SOC”) and the SOC alone by using a 2-cohort design. The study evaluates the pathological complete response (pCR) rates of the two cohorts relative to a null hypothesis, which is a pCR rate of ≤ 0.6. The success of each cohort in rejecting the null hypotheses will be evaluated.

The INVINCIBLE-4 Study is a randomised open-label, multicentre study to determine the clinical activity, safety, and tolerability of INT230-6 in patients with early-stage, operable triple-negative breast cancer (TNBC) who undergo SOC treatment and SOC alone. The primary endpoint is pCR in the primary tumour and affected lymph nodes. In the amended protocol, patients will be randomised to receive a regimen of one dose of INT230-6 followed by SOC, which consists of pembrolizumab, anthracyclines, carboplatin, cyclophosphamide, and paclitaxel, or to SOC alone.

The INVINCIBLE-4 Study reopens following a pause in patient accrual to evaluate skin irritation issues seen in some patients. In March 2026, a protocol amendment was submitted to Swissmedic and the Swiss Ethics Committee to resume enrolment using a slightly lower drug-to-tumour volume ratio and a single injection of INT230-6. Prior to the pause, 14 patients were treated, seven with the combination and seven received the SOC alone. Patients receiving INT230-6 prior to the SOC reported a favourable trend towards much fewer overall grade 3 or higher adverse events and immune-related adverse events compared to those patients receiving the SOC alone. The INVINCIBLE-4 Study is expected to enrol an additional 47 patients in Switzerland and France.

“Many TNBC patients undergoing SOC treatment alone fail to achieve a pathological complete response at the time of surgery, especially in larger tumour sizes. Early data indicates that INT230-6 has the potential to fill this unmet need for aggressive subtypes, such as TNBC, through its anti-cancer mechanisms of action that cause tumour cell necrosis and ignite an anti-cancer immune-based response,” said Markus Joerger, MD-PhD from the Department of Medical Oncology and Hematology at Health Ostschweiz, Professor of Medicine at the University of Basel, Co-Chair of the SCI’s Project Group for Developmental Therapeutics and coordinating investigator of the trial. “The ability for INT230-6 to induce necrosis and activate immune effects before a patient’s surgery with reduction in toxicity would be a major advance for the treatment of breast cancer and potentially many other cancers.”

“We are excited to have restarted our Phase II study in presurgical triple-negative breast cancer. Triple-negative is a deadly and aggressive form of breast cancer, and patients having local disease currently undergo a harsh six-month regimen whereby a small percentage can die from the SOC before their surgery,” said Intensity Therapeutics’ Founder, Chairman, and CEO, Lewis H. Bender. “We believe that the new dosing regimen can continue to show favorable overall safety, a meaningful improvement in the percentage of patients who achieve pCR, and ultimately an improved event-free survival.”